Rudi Van den Eynde has been Head of Thematic Global Equity at Candriam since 2011, and manager of our flagship Biotechnology strategy for more than 24 years. In his role at Candriam and our predecessor companies since 1987, Rudi has accrued more than three decades of investment management experience in a variety of functions across multiple asset classes. His experience includes currency trading, and institutional client and private client management. He is a voting member of the Economic Outlook Committee at Candriam.
Discover the latest articles by Rudi Van den Eynde
Outlook 2024, Rudi Van den Eynde, Antoine Hamoir
Healthcare sector, though not in as good shape as the pandemic's end, exhibits resilience with promising indicators, when the economy may start coughing.
Malgorzata Kluba, Rudi Van den Eynde, Oncology, Equities
World Cancer Day 2023
And we would rather not have to go through this – which would mean we won the battle and cancer is curable.
Outlook 2023, Rudi Van den Eynde
Building a New World: Thematic Investments
In the United States Antonín Dvořák composed the New World Symphony in 1893 and Neil Armstrong took it on a cassette to the moon. Rudi Van den Eynde takes it global, presenting us a New World of long-term trends.
Q&A, Healthcare, Rudi Van den Eynde
Biotech investing: is there a doctor in the house?
Rudi Van Den Eynde, Head of Thematic Global Equity at
Candriam, answers investors’ questions about a sector where
depth of specialist knowledge is a prerequisite to consistent
stock selection success.
Oncology, Q&A, Rudi Van den Eynde, Equities
Investing in oncology: forewarned is forearmed
Rudi Van Den Eynde, Co-Head of Thematic Global Equity, and Linden Thomson, CFA, Senior Portfolio Manager, explain to investors the approach they used to create and develop an investment strategy in the oncology sector.